{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:14:40Z","timestamp":1762431280098},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:p> PURPOSE: To determine whether the neurotoxicity of paclitaxel 250 mg\/m<jats:sup>2<\/jats:sup> given over 3 hours every 3 weeks could be reduced by pretreatment with amifostine 910 mg\/m<jats:sup>2<\/jats:sup>. Secondary objectives included comparing myelosuppression, myalgias, and response rates of the two groups. <\/jats:p><jats:p> PATIENTS AND METHODS: Forty womenwith metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2). All were assessable for toxicity, and 37 were assessable for response. At baseline and after each cycle, all patients completed questionnaires for neurologic symptoms and had standardized neurologic examinations, including objective assessments of power and vibration sense. In addition, standard follow-up assessments for other toxicities and tumor response were undertaken. Changes from baseline after courses 1, 2, and 3 were assessed. The sample size was sufficient to detect a 50% improvement in the expected determination in sensory change. <\/jats:p><jats:p> RESULTS: There were no differences observed in any of the measures of neurotoxicity. Other toxicity was similar in arms 1 and 2, including hair loss (95% v 90%), neurosensory changes (100% v 100%), fatigue\/lethargy (85% v 90%), myalgia (95% v 90%), and grade 4 neutropenia (47% v 60%). Nausea, vomiting, dizziness, hypotension, and sneezing were more common in the amifostine arm. Response rates (22.2% v 36.8%) and paclitaxel pharmacokinetics were not significantly different. <\/jats:p><jats:p> CONCLUSION: There was no protection from paclitaxel-related neurotoxicity or hematologic toxicity in this study. These results suggest that the mechanism of action of paclitaxel-related toxic effects is not amenable to the cytoprotective action of amifostine. <\/jats:p>","DOI":"10.1200\/jco.1999.17.10.3038","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:56:34Z","timestamp":1487919394000},"page":"3038-3047","source":"Crossref","is-referenced-by-count":67,"title":["Randomized Phase II Study of High-Dose Paclitaxel With or Without Amifostine in Patients With Metastatic Breast Cancer"],"prefix":"10.1200","volume":"17","author":[{"given":"K.","family":"Gelmon","sequence":"first","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bryce","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tolcher","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mayer","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Zee","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Blackstein","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tomiak","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yau","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Batist","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Iglesias","sequence":"additional","affiliation":[{"name":"From the British Columbia Cancer Agency, Vancouver; National Cancer Institute of Canada Clinical Trials Group, Kingston; Mount Sinai Hospital and Eli Lilly Company, Toronto; Ottawa Regional Cancer Centre, Ottawa; and McGill University, Montreal, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-3038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"R2-3038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"R3-3038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1165"},{"key":"R4-3038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1152"},{"key":"R5-3038","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350310"},{"key":"R6-3038","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(81)90017-2"},{"key":"R7-3038","doi-asserted-by":"publisher","DOI":"10.1007\/BF01611731"},{"key":"R8-3038","unstructured":"Rowinsky  EK,  Eisenhauer  EA,  Chaudhry  V, et al: Clinical toxicities encountered with paclitaxel (Taxol).  Semin Oncol 20:1,1993-15,  (supple 3)"},{"key":"R9-3038","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.1995.05030161.x"},{"key":"R10-3038","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059220"},{"key":"R11-3038","unstructured":"Yuhas  JM,  Spellman  JM,  Culo  F: The role of WR-2721 in radiotherapy and\/or chemotherapy.  Cancer Clin Trials 3:211,1980-216,"},{"key":"R12-3038","doi-asserted-by":"crossref","unstructured":"Calabro Jones  PM,  Fahey  RC,  Smoluk  GD, et al: Alkaline phosphatase promotes radioprotection and accumulation of WR 1065 in V79-171 cells incubated in medium containing WR 2721.  Int J Radiat Biol 47:23,1985-27,","DOI":"10.1080\/09553008514550041"},{"key":"R13-3038","unstructured":"Yuhas  JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2(3-aminopropylamino)-ethylphosphorothioic acid.  Cancer Res 40:1519,1980-1524,"},{"key":"R15-3038","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00221-9"},{"key":"R16-3038","unstructured":"Paine  GD,  Taylor  CW,  Lopez  MH, et al: Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immunodeficient mouse: Preliminary results.  Semin Oncol 23:35,1996-39,  (suppl 8)"},{"key":"R17-3038","unstructured":"Treskes  M,  Boven  E,  Holwerda  U, et al: Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR 2721 in the mouse.  Cancer Res 52:2257,1992-2260,"},{"key":"R18-3038","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90084-1"},{"key":"R19-3038","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A"},{"key":"R20-3038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2101"},{"key":"R21-3038","unstructured":"DiPaola  R,  Rodriguez  R,  Recio  A, et al: A phase I study of paclitaxel and amifostine in patients with advanced malignancies.  Proc Am Soc Clin Oncol 15:488,1996,  (abstr)"},{"key":"R22-3038","unstructured":"Harris  JW,  Rahman  A,  Bok-Ryang  K, et al: Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome p450 3A4 and an unknown p450 enzyme.  Cancer Res 54:4026,1994-4035,"},{"key":"R23-3038","doi-asserted-by":"publisher","DOI":"10.2307\/2983604"},{"key":"R26-3038","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(86)90203-8"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.10.3038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:33:47Z","timestamp":1653514427000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.10.3038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1200\/JCO.1999.17.10.3038"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.10.3038","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}